Health & Medicine Theories

Claims circulate that pharmaceutical companies or medical institutions suppress Repatha (evolocumab, a PCSK9 inhibitor approved by the FDA in 2015) or effective alternatives to statins. The claim has no documentary basis. Repatha is FDA-approved, actively marketed by Amgen, and available by prescription in more than 60 countries. Its limited uptake relative to statins reflects cost, insurance coverage, and prescribing guidelines — not suppression. Statins remain the first-line standard of care because they are proven, inexpensive, and widely effective; PCSK9 inhibitors are used as second-line or add-on therapy for high-risk patients who cannot tolerate or do not respond adequately to statins.